History

Founded in 2006, NeoStem has undergone extensive transformations in its history to become a leader in the emerging cellular therapy industry.  Today, our business includes the development of novel proprietary cell therapy products as well as a revenue generating contract development and manufacturing service business.

We believe that NeoStem is ideally positioned to significantly build upon its leadership role in the cell therapy industry allowing us to reach our goal of becoming the premier cell therapy company.

Key Milestones


2014

  • NeoStem signs agreement to acquire California Stem Cell Learn More »
  • Begins research collaboration for treatment of skin wounds in scleroderma – Learn More »
  • Announced second research collaboration with Mass. Eye and Ear/Schepens Eye Research Institute exploring NeoStem’s VSEL™ Technology for retinal repair Learn More »
  • Expanded Treg international patent portfolio with granting of patent in Japan Learn More »
  • Expanded CD34 cell patent portfolio with new US and European patent allowances Learn More »

2013

  • Completed patient enrollment in Phase 2 AMR-001 trial for prevention of adverse cardiovascular events following a heart attack. Learn More »
  • NeoStem ranked #1 fastest growing company in Tri-State region on Deloitte’s 2012 Technology Fast 500™ for second year in a row. Learn More »
  • NeoStem begins trading on NASDAQ stock market. Learn More »
  • Advances autoimmune platform through UCSF collaboration. Learn More »
  • Held Second International Vatican Adult Stem Cell Conference, in partnership with the Vatican’s Pontifical Council for Culture in April. Learn More »
  • Further expansions of NeoStem’s cardiovascular disease intellectual property coverage. Learn More »

2012

  • Began patient enrollment for Phase 2 AMR-001 trial for prevention of adverse cardiovascular events following a heart attack. Learn More »
  • Expanded NeoStem’s cardiovascular disease intellectual property protection coverage beyond target indication for AMR-001. Learn More »
  • Awarded $595,252 grant from NIAID for the development of VSELTM Technology for radiation exposure. Learn More »
  • Awarded $1.2 million grant from NIH for the first clinical study of VSELTM Technology in humans for periodontitis. Learn More »
  • NeoStem ranked #1 fastest growing company in Tri-State region on Deloitte’s 2012 Technology Fast 500™. Learn More »

2011

  • Held First International Vatican Adult Stem Cell Conference, in partnership with the Vatican’s Pontifical Council for Culture in November. Learn More »
  • Acquired Amorcyte with a Phase 2 ready asset for acute myocardial infarction and a Phase 1 ready asset for congestive heart failure. Learn More »
  • Acquired Progenitor Cell Therapy, whose services include cell therapy, contract manufacturing, and cord blood banking
  • Acquired an 80% ownership of Athelos, a company developing a T-cell therapeutic with potential for a range of auto-immune conditions. Learn More »
  • Awarded and received over $1.7 million from Department of Defense Peer Reviewed Medical Research Program to employ VSEL™ technology to treat osteoporosis and improve bone health. Learn More »

2010

  • Awarded contract with U.S. Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research Center to evaluate the use of adult stem cells for rapid wound healing. Learn More »
  • NeoStem named “Best Stem Cell Company” in The New Economy’s 2010 Biotech Awards. Learn More »
  • Announced breakthrough partnership between the Vatican’s Pontifical Council for Culture and the Stem For Life Foundation. Learn More »
  • PCT announced the first stage of its Allendale facility build complete *

* Prior to NeoStem acquisition

For Key Milestones in the history of Progenitor Cell Therapy, please visit pctcelltherapy.com/company/history/

NeoStem - Cell Therapy Development - Investors